Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2015

View Archived Issues

Strategic Science and Technologies begins phase I study of topical sildenafil

RiVax ricin toxin vaccine protective in macaque model

Bio-Path initiates phase II trial of BP-100-1.01 in patients with AML

Panoptes Pharma concludes license agreement with Mediolanum for PP-001

Vaxxas' Series B financing to fund vaccine development

Hyperion initiates pediatric study of Ravicti for urea cycle disorders

Apellis Pharmaceuticals begins phase I testing of APL-2

Galapagos, Rega Institute and University Hospital of Heidelberg receive HBV therapy grant

Novo Nordisk funds diabetes research at Karolinska Institutet

Repurposed sorafenib shows promising antiviral activity

Emergent BioSolutions presents results of phase II study of AV-7909 for anthrax

Actelion patents LXA4R agonists

NeED Pharma presents new viral entry inhibitors

Italian and U.S. scientists disclose dual FAAH inhibitors/DRD3 modulators

MMV, Drexel University and University of Washington patent new antimalarials

Novartis patent reports new complement factor B inhibitors

GSK acquires vaccine company GlycoVaxyn

FDA grants orphan drug designation to Reolysin for ovarian cancer

Heron Therapeutics begins phase I study of HTX-011

Valneva completes Dukoral acquisition

Enzo Biochem develops flow cytometry assay for cervical cancer prognosis

FDA advisory committees set date to jointly review talimogene laherparepvec BLA

AbbVie seeks Japanese approval for oral two direct-acting antiviral treatment for HCV

Anika Therapeutics files for U.S. and E.U. approval of Cingal for osteoarthritis of the knee

Synthetic Biologics reports topline data from phase Ib trial of SYN-004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...